dyslipidemia
Start with the big picture
LDL-C is the primary lipid target in this source, with goals varying by risk; triglycerides and non-HDL-C are secondary measures. High-intensity statins can substantially lower LDL-C, while treatment choice and monitoring take account of patient risk, comorbidities, tolerability, and potential interactions. The topic also surveys non-statin therapies, including ezetimibe, PCSK9 inhibitors, bempedoic acid, bile acid sequestrants, fibrates, and omega-3 fatty acids, each with distinct roles and considerations. Lifestyle measures—including a heart-healthy diet, exercise, weight management, and smoking cessation—are presented as a foundation of care. This preview introduces those principles; the full lesson develops the therapies, mechanisms, and practical approach in more detail.
What you'll learn
- Identify LDL-C as the primary target and recognize secondary lipid goals.
- Describe the role of high-intensity statins in LDL-C reduction.
- Compare the major non-statin therapy options and their key considerations.
- Recognize lifestyle measures that support dyslipidemia management.
- Outline monitoring and medication-safety considerations described in the topic.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
